Advanced triple-negative breast cancer: immunotherapy, ADCs and other choices

Recheck the information used to choose treatment

Triple-negative means the cancer lacks the usual estrogen, progesterone and HER2-positive targets. At recurrence, a new biopsy may help confirm the current biology. Keep the exact HER2 score because low expression can matter for some antibody-drug conjugate decisions.

Ask whether the team needs a current PD-L1 test or inherited genetic testing. The specimen, assay and reporting method matter. A report from the original early cancer may not answer every question about the current advanced disease.

Sources and references: [1] [2]

When immunotherapy enters the first-line discussion

For appropriately selected advanced TNBC with PD-L1 combined positive score of at least 10, pembrolizumab with chemotherapy is an established first-line option. The prior treatment history and interval since earlier therapy influence whether the evidence applies.

Ask which chemotherapy partner is proposed and why. Immune-related side effects add a different monitoring burden, especially for someone with autoimmune disease or prior immune complications. A PD-L1 result should be interpreted in the actual advanced-disease setting.

Sources and references: [1] [3]

Choosing chemotherapy when it is the main approach

The choice depends on medicines already received, how long the earlier response lasted and current organ function. Some people receive one drug at a time; a combination may be discussed when the clinical situation needs a different balance of response and toxicity.

Bring details of persistent numbness, low blood counts or other previous complications. These can be decisive when comparing drugs. Ask what symptom improvement or scan change is expected and when the team will decide whether to continue.

Sources and references: [1]

What an inherited BRCA finding may add

A pathogenic germline BRCA1 or BRCA2 variant can support a PARP inhibitor discussion in eligible HER2-negative advanced breast cancer. It also has implications for inherited risk and relatives. The testing and counseling pathway should address both issues.

A tumor-only BRCA result may need separate germline confirmation. A variant of uncertain significance is not the same as a pathogenic finding. Ask the clinician to identify the exact result that would support a treatment change and which options it adds to the current sequence.

Sources and references: [4] [1]

Where antibody-drug conjugates fit

ADCs link an antibody to a cell-killing payload. Sacituzumab govitecan has an established role after prior therapy in advanced TNBC. Other ADC decisions may depend on HER2 expression, previous treatment and the drug's particular indication.

The useful comparison includes the target, payload, prior ADC exposure and adverse effects. Ask why the proposed ADC is preferred over another chemotherapy or a trial. Similar names can refer to different medicines, so keep the full generic drug name in your records.

Sources and references: [1] [5]

Review the plan again at progression

When disease progresses, the team reassesses its pace, sites and remaining options. A new tissue or molecular assessment may be useful if it can change treatment. Clinical trials can be discussed before the last standard option has been used, particularly when a study requires a specific treatment line.

Ask what information is missing for the next decision and whether waiting for it is reasonable. If symptoms need urgent control, the team may need to treat while completing other assessments. The timetable should follow the clinical need.

Sources and references: [1]

Make side-effect management part of the regimen

Low counts and infection risk, diarrhea, nausea or neuropathy can affect treatment choice and dosing. ADCs and immunotherapy have their own monitoring needs. Tell the team how symptoms affect eating, walking and daily responsibilities.

Get written instructions for fever, severe diarrhea, breathlessness or sudden deterioration. Symptom and palliative care can be provided alongside cancer treatment. If treatment is being considered away from home, clarify who will handle urgent problems and laboratory checks between visits.

Sources and references: [1] [6]

A focused advanced TNBC consultation

Fudan University Shanghai Cancer Center has a breast cancer multidisciplinary service. Prepare the current pathology, PD-L1 and BRCA reports, latest scan images and a treatment timeline. The early-TNBC guide addresses the separate before-surgery decision.

EastMedGo can help organize a Shanghai inquiry around your next treatment choice and clarify what the clinical service needs to review. We can help clarify appointment logistics, coordination costs, required assessment visits and the receiving team's current drug or trial pathway.

Sources and references: [7]

Common questions